Treatment with levosimendan in an experimental model of early ventilator-induced diaphragmatic dysfunction

ABSTRACT Introduction: Mechanical ventilation (MV) is a life-saving approach in critically ill patients. However, it may affect the diaphragmatic structure and function, beyond the lungs. Levosimendan is a calcium sensitizer widely used in clinics to improve cardiac contractility in acute heart failure patients. In vitro studies have demonstrated that levosimendan increased force-generating capacity of the diaphragm in chronic obstructive pulmonary disease patients. Thus the aim of this study was to evaluate the effects of levosimendan administration in an animal model of ventilator-induced diaphragmatic dysfunction (VIDD) on muscle contraction and diaphragm muscle cell viability. Methods: Sprague-Dawley rats underwent prolonged MV (5 hours). VIDD+Levo group received a starting bolus of levosimendan immediately after intratracheal intubation and then an intravenous infusion of levosimendan throughout the study. Diaphragms were collected for ex vivo contractility measurement (with electric stimulation), histological analysis and Western blot analysis. Healthy rats were used as the control. Results: Levosimendan treatment maintained an adequate mean arterial pressure during the entire experimental protocol, preserved levels of autophagy-related proteins (LC3BI and LC3BII) and the muscular cell diameter demonstrated by histological analysis. Levosimendan did not affect the diaphragmatic contraction or the levels of proteins involved in the protein degradation (atrogin). Conclusions: Our data suggest that levosimendan preserves muscular cell structure (cross-sectional area) and muscle autophagy after 5 hours of MV in a rat model of VIDD. However, levosimendan did not improve diaphragm contractile efficiency.

[1]  Daniel K. Benvenuti,et al.  Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study. , 2023, The Lancet. Respiratory medicine.

[2]  G. Foti,et al.  Ultrasound Versus Computed Tomography for Diaphragmatic Thickness and Skeletal Muscle Index during Mechanical Ventilation , 2022, Diagnostics.

[3]  J. Laffey,et al.  Monitoring Lung Injury Severity and Ventilation Intensity during Mechanical Ventilation. , 2022, Seminars in respiratory and critical care medicine.

[4]  M. Girardis,et al.  Levosimendan in intensive care and emergency medicine: literature update and expert recommendations for optimal efficacy and safety , 2022, Journal of Anesthesia, Analgesia and Critical Care.

[5]  R. J. Omeljaniuk,et al.  Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury , 2021, Drug Target Insights.

[6]  M. Braga,et al.  Low skeletal muscle index and myosteatosis as predictors of mortality in critically ill surgical patients. , 2021, Nutrition.

[7]  J. Laffey,et al.  Emerging pharmacological therapies for ARDS: COVID-19 and beyond , 2020, Intensive Care Medicine.

[8]  A. Parkhomenko,et al.  Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use , 2020, Journal of cardiovascular pharmacology.

[9]  G. Gamba,et al.  Ethical Considerations in Animal Research: The Principle of 3R's. , 2020, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[10]  L. Brochard,et al.  Effects of levosimendan on respiratory muscle function in patients weaning from mechanical ventilation , 2019, Intensive Care Medicine.

[11]  A. Torsello,et al.  Angiotensin-(1–7) exerts a protective action in a rat model of ventilator-induced diaphragmatic dysfunction , 2019, Intensive Care Medicine Experimental.

[12]  A. Demoule,et al.  Diaphragm dysfunction during weaning from mechanical ventilation: an underestimated phenomenon with clinical implications , 2018, Critical Care.

[13]  A. Cohen-Solal,et al.  The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion Nieminen, , 2022 .

[14]  G. Scheffer,et al.  Levosimendan affects oxidative and inflammatory pathways in the diaphragm of ventilated endotoxemic mice , 2015, Critical Care.

[15]  A. Girbes,et al.  Diaphragm fiber strength is reduced in critically ill patients and restored by a troponin activator. , 2014, American journal of respiratory and critical care medicine.

[16]  S. Powers,et al.  Ventilator-induced diaphragm dysfunction: cause and effect. , 2013, American journal of physiology. Regulatory, integrative and comparative physiology.

[17]  D. Stegeman,et al.  The calcium sensitizer levosimendan improves human diaphragm function. , 2012, American journal of respiratory and critical care medicine.

[18]  L. Papazian,et al.  The role of neuromuscular blockers in ARDS: benefits and risks , 2012, Current opinion in critical care.

[19]  M. Tobin,et al.  Narrative Review: Ventilator-Induced Respiratory Muscle Weakness , 2010, Annals of Internal Medicine.

[20]  G. Scheffer,et al.  Toll-like Receptor 4 Signaling in Ventilator-induced Diaphragm Atrophy , 2010, Anesthesiology.

[21]  S. Powers,et al.  Prolonged mechanical ventilation alters diaphragmatic structure and function , 2009, Critical care medicine.

[22]  E. Moilanen,et al.  Effects of levo‐ and dextrosimendan on NF‐κB‐mediated transcription, iNOS expression and NO production in response to inflammatory stimuli , 2008, British journal of pharmacology.

[23]  S. Powers,et al.  Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. , 2008, Physiological reviews.

[24]  M. Decramer,et al.  Infusions of rocuronium and cisatracurium exert different effects on rat diaphragm function , 2007, Intensive Care Medicine.

[25]  M. Decramer,et al.  Rocuronium exacerbates mechanical ventilation–induced diaphragm dysfunction in rats , 2006, Critical care medicine.

[26]  S. Powers,et al.  Mechanical ventilation depresses protein synthesis in the rat diaphragm. , 2004, American journal of respiratory and critical care medicine.

[27]  T. Vassilakopoulos,et al.  Ventilator-induced diaphragmatic dysfunction. , 2004, American journal of respiratory and critical care medicine.

[28]  J. Cleland,et al.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.

[29]  H. Westerblad,et al.  Contractile response of skeletal muscle to low peroxide concentrations: myofibrillar calcium sensitivity as a likely target for redox-modulation. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  J. Levijoki,et al.  Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. , 1995, Journal of molecular and cellular cardiology.

[31]  N. Kalkkinen,et al.  Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. , 1994, The Journal of biological chemistry.

[32]  D. Singer,et al.  Abnormalities of diaphragmatic muscle in neonates with ventilated lungs. , 1988, The Journal of pediatrics.

[33]  L. Heunks,et al.  Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[34]  A. Wagstaff,et al.  Levosimendan , 2012, Drugs.

[35]  J. Papp,et al.  STEERING COMMITTEE AND INVESTIGATORS OF THE LEVOSIMENDAN INFUSION VERSUS DOBUTAMINE (LIDO) STUDY. EFFICACY AND SAFETY OF INTRAVENOUS LEVOSIMENDAN COMPARED WITH DOBUTAMINE IN SEVERE LOWOUTPUT HEART FAILURE (THE LIDO STUDY): A RANDOMISED DOUBLEBLIND TRIAL , 2002 .

[36]  D. Dreyfuss,et al.  Ventilator-induced lung injury: lessons from experimental studies. , 1998, American journal of respiratory and critical care medicine.